we discuss ideas like this as they happen in more detail. All active investors are welcome to join on a free trial and ask any question in our chat room full of sophisticated traders and investors.This is yet another of our articles, in which we attempt to closely monitor each of the newly listed preferred stocks and baby bonds in the first few daysAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions wit ...

we discuss ideas like this as they happen in more detail. All active investors are welcome to join on a free trial and ask any question in our chat room full of sophisticated traders and investors.This is yet another of our articles, in which we attempt to closely monitor each of the newly listed preferred stocks and baby bonds in the first few daysAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions wit ...

Core Viewpoint - Bruker Corporation's recent earnings report indicates a decline in both adjusted earnings per share and revenues, raising concerns about future performance and prompting a downward revision of financial guidance for 2025 [2][10][11]. Financial Performance - Adjusted EPS for Q2 2025 was 32 cents, down 38.5% year over year, and missed the Zacks Consensus Estimate by 3.03% [2]. - Q2 revenues were $797.4 million, a decrease of 0.4% year over year, but slightly exceeded the Zacks Consensus Estimate by 0.11% [3]. - Organic revenues fell by 7% when excluding the positive impacts from acquisitions and foreign currency rates [3]. Geographic Revenue Breakdown - U.S. revenues decreased by 8.5% year over year to $222.9 million [4]. - European revenues fell by 1.2% to $272.5 million, while Asia Pacific revenues increased by 6.8% to $242.1 million [4]. Segment Analysis - Revenues in the BSI segment decreased by 0.3% to $733.2 million, with the BioSpin Group experiencing a 10.2% decline to $195.3 million due to weaker demand [5]. - CALID's revenues rose by 7.6% to $285.8 million, attributed to prior-year acquisitions, while NANO group revenues dipped slightly by 0.2% to $252.1 million [6]. - The BEST segment's revenues fell by 4.1% to $66.3 million, impacted by softness in the clinical MRI market [6]. Margin Performance - Gross profit declined by 6.9% to $357.9 million, with gross margin contracting by 315 basis points to 44.9% due to a 5.6% rise in the cost of revenues [7]. - Adjusted operating profit was $26.3 million, down 63% year over year, with adjusted operating margin contracting by 558 basis points to 3.2% [8]. Financial Position - Cash and cash equivalents at the end of Q2 2025 were $92 million, down from $184.2 million at the end of Q1 [9]. - Total long-term debt increased to $2.44 billion from $2.11 billion at the end of the previous quarter [9]. - Cumulative net cash used in operating activities was $127.5 million, compared to a cash inflow of $1.1 million during the same period last year [9]. 2025 Guidance - The company has revised its revenue guidance for 2025 to a range of $3.43-$3.50 billion, down from the previous estimate of $3.48-$3.55 billion, indicating a projected growth of 2% to 4% year over year [10][11]. - Adjusted EPS guidance for the year is now expected to be between $1.95 and $2.05, down from $2.40-$2.48 [11]. Estimate Trends - Consensus estimates have trended downward, with a significant shift of -38.69% noted in the past month [12]. VGM Scores - Bruker currently holds a poor Growth Score of F, a Momentum Score of F, and a Value Score of F, placing it in the fifth quintile for investment strategy [13]. Outlook - The downward trend in estimates suggests a challenging outlook for the stock, reflected in its Zacks Rank of 5 (Strong Sell) [14].

Core Insights - The domestic liquid chromatography-mass spectrometry (LC-MS) market in China is experiencing a "dual increase" in both volume and value, with 396 units awarded in tenders amounting to 1.252 billion yuan in the first half of 2025, indicating a shift towards high-end products [5][10][25] - The global mass spectrometry market reached $7.46 billion in sales in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 6.5%, potentially reaching $10.91 billion by 2031 [3] Market Demand Expansion - In the first half of 2025, the LC-MS market showed a total of 396 units awarded, a year-on-year increase of 27.74%, with a total tender amount of 1.252 billion yuan, reflecting a 33.33% increase, indicating a clear trend towards high-end product procurement [5][10] - Monthly trends reveal a "wave-like" progression, with significant spikes in January and June due to budget releases and project initiations [8] - The average tender price for LC-MS equipment rose to 3.162 million yuan, up from 3.029 million yuan in the previous year, indicating a growing demand for high-end products [5] Procurement Unit Analysis - Higher education research institutions and the healthcare system are the main drivers of the market, with universities purchasing 152 units (38.4% of total) worth 538 million yuan (43.0% of total) [10] - The healthcare system procured 105 units (26.5% of total) for 308 million yuan (24.6% of total), driven by the expansion of clinical mass spectrometry applications [10] Regional Tender Analysis - The procurement landscape shows a "strong East, weak West" pattern, with East China, Central South, and North China accounting for 74.8% of total tenders [13] - East China remains the most active region, benefiting from the construction of national medical centers, with Guangdong province leading in procurement across various sectors [13] Brand Landscape - The market is dominated by seven major imported brands, with imported LC-MS instruments accounting for 86.39% of total tenders, significantly outpacing domestic brands [14][18] - Thermo Fisher and SCIEX lead the market, together holding over 60% of the market share, with Thermo Fisher achieving a tender amount of 318 million yuan [18] Domestic Brand Development - Domestic manufacturers are showing rapid growth, with nearly 25 companies entering the market, demonstrating significant advantages in specific application areas [21] - Notable domestic brands like Hangzhou Kailai and Shandong Yingsheng have made significant inroads in the clinical testing market [22][24] - The increasing demand for high-end equipment in research institutions indicates a shift in market dynamics, with domestic brands gaining recognition [25]

Group 1 - The article emphasizes the importance of diversifying viewpoints in stock analysis and investing, referencing the Japanese proverb "他山之石" which highlights the value of multiple perspectives [1] - It suggests that understanding fundamental aspects is crucial for investment success, akin to how a rock supports a mountain [1] - The author expresses a commitment to covering a wide range of assets to identify the best investment opportunities [1] Group 2 - The article includes a disclosure indicating a beneficial long position in the shares of BRKR and TECH, either through stock ownership or derivatives [2] - It clarifies that the article reflects the author's own opinions and is not influenced by compensation from any company mentioned [2] - The disclosure also states that the author has no business relationship with any of the companies discussed [2]

Core Insights - Bruker Corporation reported adjusted earnings per share (EPS) of 32 cents for Q2 2025, a decline of 38.5% year over year, missing the Zacks Consensus Estimate by 3.03% [1][7] - The company's revenues for Q2 2025 were $797.4 million, down 0.4% year over year, but slightly above the Zacks Consensus Estimate by 0.11% [2][7] - Bruker has lowered its full-year guidance for 2025 due to weak demand and other market challenges [10][11] Revenue Analysis - Q2 2025 revenues were $797.4 million, reflecting a 0.4% decrease year over year, with organic revenues down 7% after accounting for acquisitions and foreign currency impacts [2][11] - U.S. revenues fell 8.5% to $222.9 million, while Asia Pacific revenues increased by 6.8% to $242.1 million [3][7] - The BSI segment's revenues decreased by 0.3% to $733.2 million, with the BioSpin Group experiencing a 10.2% decline [4][5] Margin Performance - Gross profit decreased by 6.9% to $357.9 million, with gross margin contracting by 315 basis points to 44.9% due to a 5.6% rise in the cost of revenues [6][8] - Adjusted operating profit fell 63% to $26.3 million, with the adjusted operating margin contracting by 558 basis points to 3.2% [8][12] Financial Position - At the end of Q2 2025, Bruker had cash and cash equivalents of $92 million, down from $184.2 million at the end of Q1 2025 [9] - Total long-term debt increased to $2.44 billion from $2.11 billion in the previous quarter [9] Guidance and Future Outlook - The company expects full-year 2025 revenues in the range of $3.43-$3.50 billion, down from previous estimates of $3.48-$3.55 billion, indicating a year-over-year growth of approximately 2% to 4% [11] - Adjusted EPS for the year is now projected to be between $1.95 and $2.05, a reduction from earlier estimates of $2.40-$2.48 [11][12] - Bruker has initiated a cost savings initiative aimed at reducing annual costs by $100 million to $120 million for fiscal year 2026 [13]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the transition period from to Commission File Number 000-30833 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 04-3110160 (State or other jurisd ...

Bruker cut its FY2025 adjusted EPS guidance from $2.40-$2.48 to $1.95-$2.05 and also lowered FY2025 sales guidance from $3.480 billion-$3.550 billion to $3.430 billion-$3.500 billion. Frank H. Laukien, Bruker's President and CEO, said, "Life-science research instruments demand is under pressure at the moment. Our second quarter came in below expectations, as we experienced challenging demand conditions in the US academic market, as well as in biopharma and industrial markets. Tariffs and a stiff currency he ...

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Bruker (BRKR) reported $797.4 million in revenue for the quarter ended June 2025, representing a year-over- year decline of 0.4%. EPS of $0.32 for the same period compares to $0.52 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $796.5 million, representing ...

Financial Data and Key Metrics Changes - Bruker's reported revenues for Q2 2025 decreased by 0.4% year over year to $797.4 million, with an organic revenue decline of 7% [16][26][27] - Non-GAAP diluted EPS was $0.32, down 39% from $0.52 in 2024, primarily due to organic revenue decline, tariff impacts, and foreign exchange headwinds [18][29] - Non-GAAP operating margin was 9%, a decrease of 480 basis points year over year, impacted by lower revenue absorption and additional costs [18][28] Business Line Data and Key Metrics Changes - The Scientific Instruments (BSI) segment experienced a 7.2% organic revenue decline, with BSI Systems declining roughly 10% [27][28] - The CALID Group revenue increased in the low teens percentage, driven by strong growth in microbiology and infection diagnostics [20] - BEST revenues declined in the low teens percentage due to softness in the clinical MRI market [21] Market Data and Key Metrics Changes - Americas revenue declined in the low double digits percentage, while European revenue also saw a similar decline [27] - Asia Pacific revenue grew in the low single digits percentage, despite a low single-digit decline in China [27] - EMEA region revenue was up in the high single digits percentage [27] Company Strategy and Development Direction - The company is expanding cost-saving initiatives, aiming to reduce annual costs by €100 million to €120 million, affecting all business areas [14][31] - Bruker is focused on reaccelerating growth in the post-genomic era, particularly in biopharma drug discovery tools [12][24] - The company anticipates a return to organic revenue growth of 200 to 300 basis points above market levels beyond 2026 [15] Management's Comments on Operating Environment and Future Outlook - Management noted that the life science research instruments market is under pressure due to U.S. academic funding headwinds and delays in China stimulus [8][9] - The company expects a flat constant exchange rate revenue growth and an organic revenue decline of 2% to 4% for fiscal year 2025 [15][32] - Management remains cautiously optimistic about a partial recovery in fiscal year 2026, driven by significant margin improvements and cost reduction initiatives [35] Other Important Information - The company is observing tariff settlements and anticipates that global biopharma and industrial companies will accelerate investments once uncertainties are resolved [11][12] - Bruker is leveraging its backlog, which has slightly decreased from seven months to 6.5 months, to manage revenue expectations [39][98] Q&A Session Summary Question: Why is the backlog not helping this year? - Management indicated that while the backlog is being utilized, production and delivery times are planned and locked in by customers, leading to a slight decrease in backlog duration from seven months to 6.5 months [39] Question: What is the expectation for ultra-high field revenue recognition? - Management does not expect ultra-high field revenue recognition in Q3 but anticipates it in Q4 [43] Question: Why were cost-saving initiatives not initiated sooner? - Management explained that initial savings programs were started earlier in the year, but the expansion of cost-saving measures was necessary due to emerging headwinds [48][50] Question: What is the outlook for fiscal year 2026? - Management expressed uncertainty about growth in 2026 but emphasized the commitment to significant margin expansion and EPS growth regardless of market conditions [51][56] Question: How is the company addressing the free cash flow burn in Q2? - Management noted unusual outflows related to tax payments, which are not expected to recur, and anticipates a return to normal cash flow levels [65][66] Question: What is the visibility into the Q4 ramp? - Management acknowledged that Q4 typically sees a significant ramp, but visibility remains challenging due to current market conditions [101]